IJS Global GEFCO UK has been granted a Wholesale Dealer Authorisation (WDA) by the UK Regulatory Body, the MHRA, for its operations at the London Heathrow site with immediate effect. Good Distribution Practice (GDP) status was also awarded to IJS Global GEFCO NL in April this year, and shows that the company fulfils strict pharmaceutical requirements of the European Commission and the World Health Organization. “In an increasingly demanding environment for distribution of medicinal products, obtaining a WDA reconfirms our commitment to offering the highest possible quality standards in support of our customers’ evolving requirements,” said Josette Wells, Director – Quality and Compliance, IJS Global GEFCO UK. “This licence is another step forward in our drive to establish an enhanced services platform for the Life Sciences and Healthcare industry.” Internationally accepted GDP guidelines play a key role in assuring transport and distribution of medicinal products for human use does not adversely impact product quality and integrity. The GDP guidelines focus on well-established pharmaceutical working procedures, and continuously improving delivery and handling expertise. IJS Global GEFCO’s operations in the Netherlands already have WDA certification. Both countries are now able to store medicinal products in full compliance with EU regulations. The logistics provider is also involved in the International Air Transport Association (IATA)’s Center of Excellence for Independent Validators in Pharmaceutical Logistics (CEIV Pharma) project, which aims to help the entire air cargo supply chain achieve pharmaceutical handling excellence. Along with the CEIV project, both certifications will allow the logistics specialist to expand its reach in the Life Sciences and Healthcare industry.